Cell cycle regulation during viral infection

Methods in Molecular Biology

Volumn 1170, Issue , 2014, Pages 165-227

  Bagga, Sumedha ^a   Bouchard, Michael J ^a  

^a NONE

Author keywords

Cell cycle; Consequences; DNA and RNA viruses; Regulation

Indexed keywords

ANAPHASE PROMOTING COMPLEX; CYCLIN DEPENDENT KINASE 1; CYCLINE; HEPATITIS B VIRUS X PROTEIN; ONCOPROTEIN; PROTEIN P53; VPR PROTEIN; DNA VIRUS;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CYTOPLASM; DNA TUMOR VIRUS; ENZYME INACTIVATION; EPSTEIN BARR VIRUS; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPESVIRIDAE; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1; INFLUENZA A VIRUS; LIVER CELL; LIVER REGENERATION; M PHASE CELL CYCLE CHECKPOINT; MITOSIS; MURINE CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; S PHASE CELL CYCLE CHECKPOINT; SARS CORONAVIRUS; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; HOST PATHOGEN INTERACTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; CELL CYCLE; DNA VIRUSES; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS DISEASES; VIRUS REPLICATION;

EID: 84922480648     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0888-2_10     Document Type: Article

References (389)

1. Nascimento R, Costa H, Parkhouse RM (2012) Virus manipulation of cell cycle. Protoplasma 249(3):519–528
2. Condit RC (2013) Principles of virology. In: Knipe DM, Howley PM (eds) Fields virology, vol 1, 6th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 21–51
3. Swanton C, Jones N (2001) Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. Int J Exp Pathol 82(1):3–13
4. Flemington EK (2001) Herpesvirus lytic replication and the cell cycle: arresting new developments. J Virol 75(10):4475–4481
5. Emmett SR, Dove B, Mahoney L, Wurm T, Hiscox JA (2005) The cell cycle and virus infection. Methods Mol Biol 296:197–218
6. Lavia P, Mileo AM, Giordano A, Paggi MG (2003) Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene 22(42):6508–6516
7. Hume AJ, Kalejta RF (2009) Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div 4:1
8. Davy C, Doorbar J (2007) G2/M cell cycle arrest in the life cycle of viruses. Virology 368(2):219–226
9. Dove B, Brooks G, Bicknell K, Wurm T, Hiscox JA (2006) Cell cycle perturbations induced by infection with the coronavirus infectious bronchitis virus and their effect on virus replication. J Virol 80(8):4147–4156
10. He Y, Xu K, Keiner B, Zhou J, Czudai V, Li T, Chen Z, Liu J, Klenk HD, Shu YL, Sun B (2010) Infl uenza A virus replication induces cell cycle arrest in G0/G1 phase. J Virol 84(24):12832–12840
11. Bouchard MJ, Navas-Martin S (2011) Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 305(2):123–143
12. Dayaram T, Marriott SJ (2008) Effect of transforming viruses on molecular mechanisms associated with cancer. J Cell Physiol 216(2):309–314
13. Saha A, Kaul R, Murakami M, Robertson ES (2010) Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol Ther 10(10):961–978
14. McLaughlin-Drubin ME, Munger K (2008) Viruses associated with human cancer. Biochim Biophys Acta 1782(3):127–150
15. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
16. Chaurushiya MS, Weitzman MD (2009) Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair (Amst) 8(9):1166–1176
17. Howley PM, Livingston DM (2009) Small DNA tumor viruses: large contributors to biomedical sciences. Virology 384(2):256–259
18. Op De Beeck A, Caillet-Fauquet P (1997) Viruses and the cell cycle. In: Meijer L, Guidet S, Philippe M (eds) Progress in cell cycle research, vol 3. Plenum Press, New York, NY, pp 1–19
19. Vousden KH (1995) Regulation of the cell cycle by viral oncoproteins. Semin Cancer Biol 6(2):109–116
20. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131–149
21. Harper JV, Brooks G (2005) The mammalian cell cycle: an overview. Methods Mol Biol 296:113–153
22. Cooper GM (2000) The cell cycle. In: Cooper GM (ed) The cell: a molecular approach, 2nd edn. Sinauer Associates, Sunderland, MA, http://www.ncbi.nlm.nih.gov/books/NBK9839
23. Cook SJ, Balmanno K, Garner A, Millar T, Taverner C, Todd D (2000) Regulation of cell cycle re-entry by growth, survival and stress signalling pathways. Biochem Soc Trans 28(2):233–240
24. Amon A (1999) The spindle checkpoint. Curr Opin Genet Dev 9(1):69–75
25. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73(6):1059–1065
26. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79(4):551–555
27. Assoian RK, Zhu X (1997) Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr Opin Cell Biol 9(1):93–98
28. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15(5): 2612–2624
29. Girard F, Strausfeld U, Fernandez A, Lamb NJ (1991) Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67(6):1169–1179
30. Walker DH, Maller JL (1991) Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354(6351): 314–317
31. Lew DJ, Kornbluth S (1996) Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8(6):795–804
32. Pines J, Hunter T (1991) Cyclin-dependent kinases: a new cell cycle motif? Trends Cell Biol 1(5):117–121
33. Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291
34. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391(6667):597–601
35. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7(3):331–342
36. Buchkovich K, Duffy LA, Harlow E (1989) The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58(6):1097–1105
37. Bracken AP, Ciro M, Cocito A, Helin K (2004) E2F target genes: unraveling the biology. Trends Biochem Sci 29(8):409–417
38. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA (1992) Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70(6):993–1006
39. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M (1999) Ubiquitination of p27 is regulated by Cdkdependent phosphorylation and trimeric complex formation. Genes Dev 13(9): 1181–1189
40. Roberts JM, Koff A, Polyak K, Firpo E, Collins S, Ohtsubo M, Massague J (1994) Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 59:31–38
41. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512
42. Alberts B, Jhonson A, Lewis J, Raff M, Roberts K, Walter P (2008) The cell cycle. In: Alberts B, Jhonson A, Lewis J, Raff M, Roberts K, Walter P (eds) Molecular biology of the cell, 5th edn. GS, New York, NY, pp 1053–1092
43. Kolupaeva V, Janssens V (2013) PP1 and PP2A phosphatases—cooperating partners in modulating retinoblastoma protein activation. FEBS J 280(2):627–643
44. Stark GR, Taylor WR (2006) Control of the G2/M transition. Mol Biotechnol 32(3): 227–248
45. Branzei D, Foiani M (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9(4):297–308
46. Lobrich M, Jeggo PA (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7(11):861–869
47. Porter LA, Donoghue DJ (2003) Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 5:335–347
48. Manchado E, Eguren M, Malumbres M (2010) The anaphase-promoting complex/ cyclosome (APC/C): cell-cycle-dependent and -independent functions. Biochem Soc Trans 38(Pt 1):65–71
49. Barford D (2011) Structure, function and mechanism of the anaphase promoting complex (APC/C). Q Rev Biophys 44(2):153–190
50. Page AM, Hieter P (1999) The anaphasepromoting complex: new subunits and regulators. Annu Rev Biochem 68:583–609
51. Peters JM (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7(9): 644–656
52. Acquaviva C, Herzog F, Kraft C, Pines J (2004) The anaphase promoting complex/ cyclosome is recruited to centromeres by the spindle assembly checkpoint. Nat Cell Biol 6(9):892–898
53. Mo M, Shahar S, Fleming SB, Mercer AA (2012) How viruses affect the cell cycle through manipulation of the APC/C. Trends Microbiol 20(9):440–448
54. Kornitzer D, Sharf R, Kleinberger T (2001) Adenovirus E4orf4 protein induces PP2Adependent growth arrest in Saccharomyces cerevisiae and interacts with the anaphasepromoting complex/cyclosome. J Cell Biol 154(2):331–344
55. Mui MZ, Roopchand DE, Gentry MS, Hallberg RL, Vogel J, Branton PE (2010) Adenovirus protein E4orf4 induces premature APCCdc20 activation in Saccharomyces cerevisiae by a protein phosphatase 2A-dependent mechanism. J Virol 84(9): 4798–4809
56. Smits VA, Medema RH (2001) Checking out the G(2)/M transition. Biochim Biophys Acta 1519(1–2):1–12
57. Lukas J, Lukas C, Bartek J (2004) Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 3(8–9):997–1007
58. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85
59. Rumschlag-Booms E, Rong L (2013) Influenza a virus entry: implications in virulence and future therapeutics. Adv Virol 2013:121924
60. La Gruta NL, Kedzierska K, Stambas J, Doherty PC (2007) A question of selfpreservation: immunopathology in influenza virus infection. Immunol Cell Biol 85(2): 85–92
61. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56(1):152–179
62. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB (1997) The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87(12):1944–1950
63. Morens DM, Fauci AS (2007) The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 195(7):1018–1028
64. Samji T (2009) Influenza A: understanding the viral life cycle. Yale J Biol Med 82(4):153–159
65. Palese P, Shaw ML (2007) Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 1647–1690
66. Couch RB (1996) Orthomyxoviruses. In: Baron S (ed) Medical microbiology, 4th edn. University of Texas medical branch at Galveston, Galveston, TX, http://www.ncbi.nlm.nih.gov/books/NBK8611/
67. Zhirnov OP, Klenk HD (2007) Control of apoptosis in infl uenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 12(8):1419–1432
68. Jiang W, Wang Q, Chen S, Gao S, Song L, Liu P, Huang W (2013) Influenza A virus NS1 induces G0/G1 cell cycle arrest by inhibiting the expression and activity of RhoA protein. J Virol 87(6):3039–3052
69. Turpin E, Luke K, Jones J, Tumpey T, Konan K, Schultz-Cherry S (2005) Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication. J Virol 79(14):8802–8811
70. Terrier O, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N’Guyen C, Lina B, Diaz JJ, Bourdon JC, Rosa-Calatrava M (2011) Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. Virol J 8:285
71. Hale BG, Randall RE, Ortin J, Jackson D (2008) The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89(Pt 10):2359–2376
72. Zhang S, Tang Q, Xu F, Xue Y, Zhen Z, Deng Y, Liu M, Chen J, Liu S, Qiu M, Liao Z, Li Z, Luo D, Shi F, Zheng Y, Bi F (2009) RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. Mol Cancer Res 7(4):570–580
73. Weber JD, Hu W, Jefcoat SC Jr, Raben DM, Baldassare JJ (1997) Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 272(52):32966–32971
74. Li H, Ung CY, Ma XH, Li BW, Low BC, Cao ZW, Chen YZ (2009) Simulation of crosstalk between small GTPase RhoA and EGFR- ERK signaling pathway via MEKK1. Bioinformatics 25(3):358–364
75. Croft DR, Olson MF (2006) The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 26(12):4612–4627
76. Engelhardt OG, Fodor E (2006) Functional association between viral and cellular transcription during infl uenza virus infection. Rev Med Virol 16(5):329–345
77. Yonaha M, Chibazakura T, Kitajima S, Yasukochi Y (1995) Cell cycle-dependent regulation of RNA polymerase II basal transcription activity. Nucleic Acids Res 23(20): 4050–4054
78. Garfinkel MS, Katze MG (1992) Translational control by infl uenza virus. Selective and capdependent translation of viral mRNAs in infected cells. J Biol Chem 267(13): 9383–9390
79. Park YW, Wilusz J, Katze MG (1999) Regulation of eukaryotic protein synthesis: selective infl uenza viral mRNA translation is mediated by the cellular RNA-binding protein GRSF-1. Proc Natl Acad Sci U S A 96(12):6694–6699
80. Pyronnet S, Dostie J, Sonenberg N (2001) Suppression of cap-dependent translation in mitosis. Genes Dev 15(16):2083–2093
81. Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS (1999) Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A 96(21): 12039–12043
82. Gozlan J, Lathey JL, Spector SA (1998) Human immunodeficiency virus type 1 induction mediated by genistein is linked to cell cycle arrest in G2. J Virol 72(10):8174–8180
83. Yuan X, Shan Y, Zhao Z, Chen J, Cong Y (2005) G0/G1 arrest and apoptosis induced by SARS-CoV 3b protein in transfected cells. Virol J 2:66
84. Yuan X, Wu J, Shan Y, Yao Z, Dong B, Chen B, Zhao Z, Wang S, Chen J, Cong Y (2006) SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 phase via the cyclin D3/pRb pathway. Virology 346(1):74–85
85. Chen CJ, Makino S (2004) Murine coronavirus replication induces cell cycle arrest in G0/ G1 phase. J Virol 78(11):5658–5669
86. Chen CJ, Sugiyama K, Kubo H, Huang C, Makino S (2004) Murine coronavirus nonstructural protein p28 arrests cell cycle in G0/G1 phase. J Virol 78(19):10410–10419
87. Weiss SR, Navas-Martin S (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69(4):635–664
88. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL (2003) The Genome sequence of the SARS- associated coronavirus. Science 300(5624):1399–1404
89. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen- Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300(5624):1394–1399
90. Compton SR, Barthold SW, Smith AL (1993) The cellular and molecular pathogenesis of coronaviruses. Lab Anim Sci 43(1):15–28
91. Wege H, Siddell S, ter Meulen V (1982) The biology and pathogenesis of coronaviruses. Curr Top Microbiol Immunol 99:165–200
92. An S, Chen CJ, Yu X, Leibowitz JL, Makino S (1999) Induction of apoptosis in murine coronavirus-infected cultured cells and demonstration of E protein as an apoptosis inducer. J Virol 73(9):7853–7859
93. Chen CJ, Makino S (2002) Murine coronavirus- induced apoptosis in 17Cl-1 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and bid cleavage. Virology 302(2):321–332
94. Belyavsky M, Belyavskaya E, Levy GA, Leibowitz JL (1998) Coronavirus MHV-3- induced apoptosis in macrophages. Virology 250(1):41–49
95. Zhu L, Anasetti C (1995) Cell cycle control of apoptosis in human leukemic T cells. J Immunol 154(1):192–200
96. Klumperman J, Locker JK, Meijer A, Horzinek MC, Geuze HJ, Rottier PJ (1994) Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol 68(10):6523–6534
97. Tooze J, Tooze S, Warren G (1984) Replication of coronavirus MHV-A59 in sac- cells: determination of the first site of budding of progeny virions. Eur J Cell Biol 33(2):281–293
98. Lowe M, Nakamura N, Warren G (1998) Golgi division and membrane traffic. Trends Cell Biol 8(1):40–44
99. Warren G (1993) Membrane partitioning during cell division. Annu Rev Biochem 62:323–348
100. Bonneau AM, Sonenberg N (1987) Involvement of the 24-kDa cap-binding protein in regulation of protein synthesis in mitosis. J Biol Chem 262(23):11134–11139
101. Thiel V, Siddell SG (1994) Internal ribosome entry in the coding region of murine hepatitis virus mRNA 5. J Gen Virol 75(Pt 11):3041–3046
102. Nishioka WK, Welsh RM (1994) Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target. J Exp Med 179(2):769–774
103. Johnston JB, Wang G, Barrett JW, Nazarian SH, Colwill K, Moran M, McFadden G (2005) Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J Virol 79(16):10750–10763
104. Gearhart TL, Bouchard MJ (2010) The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol 84(6):2675–2686
105. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S (2011) An overview of HCV molecular biology, replication and immune responses. Virol J 8:161
106. Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436(7053):933–938
107. Sy T, Jamal MM (2006) Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 3(2):41–46
108. Rosen HR (2011) Clinical practice. Chronic hepatitis C infection. N Engl J Med 364(25):2429–2438
109. Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368(20):1907–1917
110. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:296
111. Ray S, Bailey J, Thomas D (2013) Hepatitis C virus. In: Knipe DM, Howley PM (eds) Fields virology, 6th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 795–824
112. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80(Pt 5):1179–1183
113. Park SH, Lim JS, Lim SY, Tiwari I, Jang KL (2011) Hepatitis C virus Core protein stimulates cell growth by down-regulating p16 expression via DNA methylation. Cancer Lett 310(1):61–68
114. Tsukiyama-Kohara K, Tone S, Maruyama I, Inoue K, Katsume A, Nuriya H, Ohmori H, Ohkawa J, Taira K, Hoshikawa Y, Shibasaki F, Reth M, Minatogawa Y, Kohara M (2004) Activation of the CKI-CDK-Rb- E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem 279(15): 14531–14541
115. Yang XJ, Liu J, Ye L, Liao QJ, Wu JG, Gao JR, She YL, Wu ZH, Ye LB (2006) HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression. Virus Res 121(2):134–143
116. Bittar C, Shrivastava S, Bhanja Chowdhury J, Rahal P, Ray RB (2013) Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. PLoS One 8(4):e62581
117. Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TY (2013) Hepatitis C virus core protein down-regulates p21(Waf1/ Cip1) and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PLoS One 8(4): e61089
118. Wang Y, Wang Y, Xu Y, Tong W, Pan T, Li J, Sun S, Shao J, Ding H, Toyoda T, Yuan Z (2011) Hepatitis C virus NS5B protein delays s phase progression in human hepatocytederived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP). J Biol Chem 286(30):26603–26615
119. Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG (2009) Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog 5(1):e1000269
120. Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM (2004) Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol 78(3):1513–1524
121. Sarfraz S, Hamid S, Siddiqui A, Hussain S, Pervez S, Alexander G (2008) Altered expression of cell cycle and apoptotic proteins in chronic hepatitis C virus infection. BMC Microbiol 8:133
122. Ruggieri A, Murdolo M, Harada T, Miyamura T, Rapicetta M (2004) Cell cycle perturbation in a human hepatoblastoma cell line constitutively expressing hepatitis C virus core protein. Arch Virol 149(1):61–74
123. Chen H, Pei R, Chen X (2013) Different response of two highly permissive cell lines upon HCV infection. Virol Sin 28(4): 202–208
124. Cho JW, Baek WK, Suh SI, Yang SH, Chang J, Sung YC, Suh MH (2001) Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver 21(2):137–142
125. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM (2000) Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 31(6):1351–1359
126. Banerjee A, Ray RB, Ray R (2010) Oncogenic potential of hepatitis C virus proteins. Viruses 2(9):2108–2133
127. Munakata T, Liang Y, Kim S, McGivern DR, Huibregtse J, Nomoto A, Lemon SM (2007) Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3(9):1335–1347
128. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9(6):400–414
129. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL (2001) p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 82(Pt 9):2235–2241
130. Nguyen H, Mudryj M, Guadalupe M, Dandekar S (2003) Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle. Virology 312(1): 245–253
131. Yao ZQ, Eisen-Vandervelde A, Ray S, Hahn YS (2003) HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1. Virology 314(1):271–282
132. Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M (2000) Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affi nity and transcriptional ability. J Biol Chem 275(44):34122–34130
133. Lo SY, Masiarz F, Hwang SB, Lai MM, Ou JH (1995) Differential subcellular localization of hepatitis C virus core gene products. Virology 213(2):455–461
134. Salvant BS, Fortunato EA, Spector DH (1998) Cell cycle dysregulation by human cytomegalovirus: infl uence of the cell cycle phase at the time of infection and effects on cyclin transcription. J Virol 72(5):3729–3741
135. Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8(9): 671–682
136. Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL, Coleman N, Alexander G (2005) Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fi brosis in chronic hepatitis C virus infection. Gastroenterology 128(1):33–42
137. Marshall A, Rushbrook S, Morris LS, Scott IS, Vowler SL, Davies SE, Coleman N, Alexander G (2005) Hepatocyte expression of minichromosome maintenance protein-2 predicts fi brosis progression after transplantation for chronic hepatitis C virus: a pilot study. Liver Transpl 11(4):427–433
138. Fehr C, Conrad KD, Niepmann M (2012) Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases. Cell Cycle 11(2): 277–285
139. Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM (2000) Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 118(1):152–162
140. Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11(2):211–219
141. Mohd Hanafi ah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specifi c antibody to HCV seroprevalence. Hepatology 57(4):1333–1342
142. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501(7466):237–241
143. Gaston KL (2012) Small DNA tumor viruses, 4th edn. Caister Academic Press, Bristol, UK
144. Gatza ML, Chandhasin C, Ducu RI, Marriott SJ (2005) Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environ Mol Mutagen 45(2–3):304–325
145. Flint SJ, Enquist LW, Racaniello VR, Skalka AM (2009) Transformation and oncogenesis. In: Flint SJ, Enquist LW, Racaniello VR, Skalka AM (eds) Principles of virology, vol 2, 3rd edn. ASM Press, New York, NY, pp 201–248
146. Helt AM, Galloway DA (2003) Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24(2):159–169
147. Moran E (1993) DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev 3(1):63–70
148. Nevins JR (1994) Cell cycle targets of the DNA tumor viruses. Curr Opin Genet Dev 4(1):130–134
149. Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2): 103–112
150. Polager S, Ginsberg D (2009) p53 and E2f: partners in life and death. Nat Rev Cancer 9(10):738–748
151. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14(19):2393–2409
152. Henley SA, Dick FA (2012) The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 7(1):10
153. Raychaudhuri P, Bagchi S, Devoto SH, Kraus VB, Moran E, Nevins JR (1991) Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes. Genes Dev 5(7):1200–1211
154. Liu X, Marmorstein R (2007) Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev 21(21):2711–2716
155. Ikeda MA, Nevins JR (1993) Identifi cation of distinct roles for separate E1A domains in disruption of E2F complexes. Mol Cell Biol 13(11):7029–7035
156. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM (1988) SV40 large tumor antigen forms a specifi c complex with the product of the retinoblastoma susceptibility gene. Cell 54(2):275–283
157. Zalvide J, DeCaprio JA, Stubdal H (2001) Binding of SV40 large T antigen to the retinoblastoma susceptibility gene product and related proteins. Methods Mol Biol 165: 213–218
158. Zalvide J, DeCaprio JA (1995) Role of pRbrelated proteins in simian virus 40 large-Tantigen- mediated transformation. Mol Cell Biol 15(10):5800–5810
159. Zalvide J, Stubdal H, DeCaprio JA (1998) The J domain of simian virus 40 large T antigen is required to functionally inactivate RB family proteins. Mol Cell Biol 18(3): 1408–1415
160. Sullivan CS, Cantalupo P, Pipas JM (2000) The molecular chaperone activity of simian virus 40 large T antigen is required to disrupt Rb-E2F family complexes by an ATPdependent mechanism. Mol Cell Biol 20(17): 6233–6243
161. Stubdal H, Zalvide J, DeCaprio JA (1996) Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. J Virol 70(5): 2781–2788
162. Pagano M, Durst M, Joswig S, Draetta G, Jansen-Durr P (1992) Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene 7(9):1681–1686
163. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 89(10): 4549–4553
164. Wu EW, Clemens KE, Heck DV, Munger K (1993) The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 67(4):2402–2407
165. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56(20):4620–4624
166. Jones DL, Munger K (1997) Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71(4):2905–2912
167. O’Shea CC, Fried M (2005) Modulation of the ARF-p53 pathway by the small DNA tumor viruses. Cell Cycle 4(3):449–452
168. Jiang D, Srinivasan A, Lozano G, Robbins PD (1993) SV40 T antigen abrogates p53- mediated transcriptional activity. Oncogene 8(10):2805–2812
169. Segawa K, Minowa A, Sugasawa K, Takano T, Hanaoka F (1993) Abrogation of p53- mediated transactivation by SV40 large T antigen. Oncogene 8(3):543–548
170. Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11(13):5013–5020
171. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278(5701):261–263
172. Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1):43–52
173. Harada JN, Shevchenko A, Shevchenko A, Pallas DC, Berk AJ (2002) Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76(18):9194–9206
174. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE (2001) Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15(23):3104–3117
175. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53. Cell 75(3):495–505
176. Pellet PE, Roizman B (2013) Herpesviridae. In: Knipe DM, Howley PM (eds) Fields virology, 6th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 1802–1820
177. Sandri-Goldin RM (2006) Alpha Herpesviruses: molecular and cellular biology. Caister Academic Press, Bristol, UK
178. Flint SJ, Enquist LW, Racaniello VR, Skalka AM Patterns of infection. In: Flint SJ, Enquist LW, Racaniello VR, Skalka AM (eds) Principles of virology vol Volume II: Pathogenesis and control, vol 2, 3rd edn. ASM Press, New York, NY, pp 134–163
179. McGeoch DJ, Rixon FJ, Davison AJ (2006) Topics in herpesvirus genomics and evolution. Virus Res 117(1):90–104
180. Dittmer DP, Damania B (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)-an update. Curr Opin Virol 3(3):238–244
181. Mesri EA, Cesarman E, Boshoff C (2010) Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 10(10):707–719
182. Cai Q, Verma SC, Lu J, Robertson ES (2010) Molecular biology of Kaposi’s sarcomaassociated herpesvirus and related oncogenesis. Adv Virus Res 78:87–142
183. Jarviluoma A, Ojala PM (2006) Cell signaling pathways engaged by KSHV. Biochim Biophys Acta 1766(1):140–158
184. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332(18):1186–1191
185. Renne R, Blackbourn D, Whitby D, Levy J, Ganem D (1998) Limited transmission of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol 72(6):5182–5188
186. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS (1998) Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity- based lymphoma cell line (BC-1). J Virol 72(2):1005–1012
187. Direkze S, Laman H (2004) Regulation of growth signalling and cell cycle by Kaposi’s sarcoma-associated herpesvirus genes. Int J Exp Pathol 85(6):305–319
188. Moore PS (2007) KSHV manipulation of the cell cycle and apoptosis. In: Arvin A, Campadelli-Fiume G, Mocarski E et al (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge
189. Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden K, Paterson H, Weiss RA, Mittnacht S (1996) Cyclin encoded by KS herpesvirus. Nature 382(6590):410
190. Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, Jung JU (1997) Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 71(3): 1984–1991
191. Laman H, Coverley D, Krude T, Laskey R, Jones N (2001) Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 21(2):624–635
192. Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA, Lu X, Mittnacht S (1999) Degradation of p27(Kip) cdk inhibitor triggered by Kaposi’s sarcoma virus cyclin- cdk6 complex. EMBO J 18(3): 644–653
193. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, Weiss RA, Mittnacht S (1997) The cyclin encoded by Kaposi’s sarcoma- associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 71(6): 4193–4198
194. Laman H, Peters G, Jones N (2001) Cyclinmediated export of human Orc1. Exp Cell Res 271(2):230–237
195. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N (1997) Herpes viral cyclin/ Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390(6656):184–187
196. Kaldis P, Ojala PM, Tong L, Makela TP, Solomon MJ (2001) CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell 12(12):3987–3999
197. Sarek G, Jarviluoma A, Ojala PM (2006) KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 107(2):725–732
198. Mann DJ, Child ES, Swanton C, Laman H, Jones N (1999) Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi’s sarcomaassociated herpesvirus. EMBO J 18(3): 654–663
199. Ojala PM, Tiainen M, Salven P, Veikkola T, Castanos-Velez E, Sarid R, Biberfeld P, Makela TP (1999) Kaposi’s sarcomaassociated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclindependent kinase 6. Cancer Res 59(19): 4984–4989
200. Verschuren EW, Klefstrom J, Evan GI, Jones N (2002) The oncogenic potential of Kaposi’s sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2(3):229–241
201. Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI (2004) The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 64(2): 581–589
202. Radkov SA, Kellam P, Boshoff C (2000) The latent nuclear antigen of Kaposi sarcomaassociated herpesvirus targets the retinoblastoma- E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 6(10):1121–1127
203. Cannon M, Philpott NJ, Cesarman E (2003) The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 77(1):57–67
204. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS (1996) Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93(25):14862–14867
205. Seaman WT, Ye D, Wang RX, Hale EE, Weisse M, Quinlivan EB (1999) Gene expression from the ORF50/K8 region of Kaposi’s sarcoma-associated herpesvirus. Virology 263(2):436–449
206. Wang SE, Wu FY, Yu Y, Hayward GS (2003) CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi’s sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol 77(17): 9590–9612
207. Wang SE, Wu FY, Fujimuro M, Zong J, Hayward SD, Hayward GS (2003) Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi’s sarcoma-associated herpesvirus (KSHV) lyticcycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J Virol 77(1):600–623
208. Wu FY, Wang SE, Tang QQ, Fujimuro M, Chiou CJ, Zheng Q, Chen H, Hayward SD, Lane MD, Hayward GS (2003) Cell cycle arrest by Kaposi’s sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p21(CIP-1). J Virol 77(16):8893–8914
209. Izumiya Y, Lin SF, Ellison TJ, Levy AM, Mayeur GL, Izumiya C, Kung HJ (2003) Cell cycle regulation by Kaposi’s sarcomaassociated herpesvirus K-bZIP: direct interaction with cyclin-CDK2 and induction of G1 growth arrest. J Virol 77(17):9652–9661
210. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K (2009) Spectrum of Epstein–Barr virus-related diseases: a pictorial review. Jpn J Radiol 27(1):4–19
211. Young LS, Rickinson AB (2004) Epstein– Barr virus: 40 years on. Nat Rev Cancer 4(10):757–768
212. Arvanitakis L, Yaseen N, Sharma S (1995) Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol 155(3):1047–1056
213. Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseno C, Gires O, Kieser A, Eick D, Sugden B, Hammerschmidt W (2005) Latent membrane protein 1 of Epstein–Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 24(10):1711–1717
214. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ (1996) Epstein–Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13(12):2541–2549
215. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, Murakami M, Cai Q, Robertson ES (2011) Epstein–Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 7(2):e1001275
216. Fukuda M, Satoh TA, Takanashi M, Hirai K, Ohnishi E, Sairenji T (2000) Inhibition of cell growth and Epstein–Barr virus reactivation by CD40 stimulation in Epstein–Barr virus- transformed B cells. Viral Immunol 13(2):215–229
217. Rodriguez A, Armstrong M, Dwyer D, Flemington E (1999) Genetic dissection of cell growth arrest functions mediated by the Epstein–Barr virus lytic gene product, Zta. J Virol 73(11):9029–9038
218. Cayrol C, Flemington EK (1996) The Epstein–Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 15(11):2748–2759
219. Swenson JJ, Mauser AE, Kaufmann WK, Kenney SC (1999) The Epstein–Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol 73(8):6540–6550
220. Michaelis M, Doerr HW, Cinatl J (2009) The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11(1):1–9
221. Huang ES, Johnson RA (2000) Human cytomegalovirus— no longer just a DNA virus. Nat Med 6(8):863–864
222. Castillo JP, Kowalik TF (2004) HCMV infection: modulating the cell cycle and cell death. Int Rev Immunol 23(1–2):113–139
223. Albrecht T, Nachtigal M, St Jeor SC, Rapp F (1976) Induction of cellular DNA synthesis and increased mitotic activity in syrian hamster embryo cells abortively infected with human cytomegalovirus. J Gen Virol 30(2):167–177
224. Gonczol E, Plotkin SA (1984) Cells infected with human cytomegalovirus release a factor(s) that stimulates cell DNA synthesis. J Gen Virol 65(Pt 10):1833–1837
225. Sinclair J, Baillie J, Bryant L, Caswell R (2000) Human cytomegalovirus mediates cell cycle progression through G(1) into early S phase in terminally differentiated cells. J Gen Virol 81(Pt 6):1553–1565
226. Dittmer D, Mocarski ES (1997) Human cytomegalovirus infection inhibits G1/S transition. J Virol 71(2):1629–1634
227. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T (1996) Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 224(1):150–160
228. Lu M, Shenk T (1996) Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. J Virol 70(12):8850–8857
229. Lu M, Shenk T (1999) Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle. J Virol 73(1):676–683
230. Wiebusch L, Hagemeier C (1999) Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle progression in G(1). J Virol 73(11):9274–9283
231. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF (2008) Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320(5877):797–799
232. Kalejta RF, Bechtel JT, Shenk T (2003) Human cytomegalovirus pp 71 stimulates cell cycle progression by inducing the proteasomedependent degradation of the retinoblastoma family of tumor suppressors. Mol Cell Biol 23(6):1885–1895
233. Kalejta RF, Shenk T (2003) Proteasomedependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp 71 protein. Proc Natl Acad Sci U S A 100(6): 3263–3268
234. Kalejta RF, Shenk T (2003) The human cytomegalovirus UL82 gene product (pp 71) accelerates progression through the G1 phase of the cell cycle. J Virol 77(6):3451–3459
235. Hagemeier C, Caswell R, Hayhurst G, Sinclair J, Kouzarides T (1994) Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 13(12):2897–2903
236. Fortunato EA, Sommer MH, Yoder K, Spector DH (1997) Identifi cation of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J Virol 71(11):8176–8185
237. Bresnahan WA, Albrecht T, Thompson EA (1998) The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein. J Biol Chem 273(34): 22075–22082
238. Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF (2009) Herpes simplex. Pediatr Rev 30(4):119–129, quiz 130
239. Song B, Liu JJ, Yeh KC, Knipe DM (2000) Herpes simplex virus infection blocks events in the G1 phase of the cell cycle. Virology 267(2):326–334
240. de Bruyn Kops A, Knipe DM (1988) Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein. Cell 55(5):857–868
241. Ehmann GL, McLean TI, Bachenheimer SL (2000) Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells. Virology 267(2):335–349
242. Olgiate J, Ehmann GL, Vidyarthi S, Hilton MJ, Bachenheimer SL (1999) Herpes simplex virus induces intracellular redistribution of E2F4 and accumulation of E2F pocket protein complexes. Virology 258(2):257–270
243. Hobbs WE 2nd, DeLuca NA (1999) Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 73(10): 8245–8255
244. Lomonte P, Everett RD (1999) Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol 73(11):9456–9467
245. Diwan P, Lacasse JJ, Schang LM (2004) Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specifi c factors. J Virol 78(17):9352–9365
246. Schang LM, Phillips J, Schaffer PA (1998) Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J Virol 72(7):5626–5637
247. Durand LO, Roizman B (2008) Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1. J Virol 82(21):10591–10599
248. Davido DJ, Von Zagorski WF, Maul GG, Schaffer PA (2003) The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0. J Virol 77(23):12603–12616
249. Hossain A, Holt T, Ciacci-Zanella J, Jones C (1997) Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection. J Gen Virol 78(Pt 12):3341–3348
250. Seeger C, Mason WS, Zoulim F (2007) Hepadnaviruses. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 2977–3029
251. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22(33):5093–5107
252. Nguyen VT, Law MG, Dore GJ (2009) Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 16(7):453–463
253. Madden CR, Slagle BL (2001) Stimulation of cellular proliferation by hepatitis B virus X protein. Dis Markers 17(3):153–157
254. Friedrich B, Wollersheim M, Brandenburg B, Foerste R, Will H, Hildt E (2005) Induction of anti-proliferative mechanisms in hepatitis B virus producing cells. J Hepatol 43(4):696–703
255. Wang T, Zhao R, Wu Y, Kong D, Zhang L, Wu D, Li C, Zhang C, Yu Z, Jin X (2011) Hepatitis B virus induces G1 phase arrest by regulating cell cycle genes in HepG2.2.15 cells. Virol J 8:231
256. Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Dong X, Gowans E, Bock CT, Torresi J (2007) Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatol 47(3):325–337
257. Casciano J, Bagga S, Yang B, Bouchard M (2012) Modulation of cell proliferation pathways by the hepatitis B virus X protein: a potential contributor to the development of hepatocellular carcinoma. In: Lau JWY (ed) Hepatocellular carcinoma-basic research. InTech, Rijeka, Croatia, pp 103–152
258. Huang YQ, Wang LW, Yan SN, Gong ZJ (2004) Effects of cell cycle on telomerase activity and on hepatitis B virus replication in HepG2 2.2.15 cells. Hepatobiliary Pancreat Dis Int 3(4):543–547
259. Ozer A, Khaoustov VI, Mearns M, Lewis DE, Genta RM, Darlington GJ, Yoffe B (1996) Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. Gastroenterology 110(5):1519–1528
260. Guidotti LG, Matzke B, Chisari FV (1997) Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice. J Virol 71(6):4804–4808
261. Guidotti LG, Matzke B, Schaller H, Chisari FV (1995) High-level hepatitis B virus replication in transgenic mice. J Virol 69(10): 6158–6169
262. Bouchard MJ, Schneider RJ (2004) The enigmatic X gene of hepatitis B virus. J Virol 78(23):12725–12734
263. Benhenda S, Cougot D, Buendia MA, Neuveut C (2009) Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res 103:75–109
264. Bouchard M, Giannakopoulos S, Wang EH, Tanese N, Schneider RJ (2001) Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway. J Virol 75(9):4247–4257
265. Benn J, Schneider RJ (1994) Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A 91(22):10350–10354
266. Benn J, Schneider RJ (1995) Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A 92(24):11215–11219
267. Koike K, Moriya K, Yotsuyanagi H, Iino S, Kurokawa K (1994) Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fi broblasts. J Clin Invest 94(1):44–49
268. Lee S, Tarn C, Wang WH, Chen S, Hullinger RL, Andrisani OM (2002) Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines. J Biol Chem 277(10):8730–8740
269. Chen HY, Tang NH, Lin N, Chen ZX, Wang XZ (2008) Hepatitis B virus X protein induces apoptosis and cell cycle deregulation through interfering with DNA repair and checkpoint responses. Hepatol Res 38(2):174–182
270. Mukherji A, Janbandhu VC, Kumar V (2007) HBx-dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem J 401(1):247–256
271. Singh AK, Swarnalatha M, Kumar V (2011) c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation. J Biol Chem 286(25): 21961–21970
272. Zhang JL, Zhao WG, Wu KL, Wang K, Zhang X, Gu CF, Li Y, Zhu Y, Wu JG (2005) Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin. Arch Virol 150(4):721–741
273. Wu JC, Merlino G, Cveklova K, Mosinger B Jr, Fausto N (1994) Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. Cancer Res 54(22): 5964–5973
274. Tarn C, Bilodeau ML, Hullinger RL, Andrisani OM (1999) Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines. J Biol Chem 274(4):2327–2336
275. Wu JC, Merlino G, Fausto N (1994) Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 91(2):674–678
276. Jung JK, Arora P, Pagano JS, Jang KL (2007) Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4acyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 67(12):5771–5778
277. Park SG, Chung C, Kang H, Kim JY, Jung G (2006) Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem 281(42):31770–31777
278. Zhu R, Li BZ, Li H, Ling YQ, Hu XQ, Zhai WR, Zhu HG (2007) Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol Int 57(6):328–336
279. Zhu YZ, Zhu R, Fan J, Pan Q, Li H, Chen Q, Zhu HG (2010) Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepat 17(2):98–107
280. Ahn JY, Jung EY, Kwun HJ, Lee CW, Sung YC, Jang KL (2002) Dual effects of hepatitis B virus X protein on the regulation of cellcycle control depending on the status of cellular p53. J Gen Virol 83(Pt 11):2765–2772
281. Park US, Park SK, Lee YI, Park JG, Lee YI (2000) Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1 → S transition via a p53-independent pathway in human hepatoma cells. Oncogene 19(30):3384–3394
282. Leach JK, Qiao L, Fang Y, Han SL, Gilfor D, Fisher PB, Grant S, Hylemon PB, Peterson D, Dent P (2003) Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3. J Gastroenterol Hepatol 18(4):376–385
283. Qiao L, Leach K, McKinstry R, Gilfor D, Yacoub A, Park JS, Grant S, Hylemon PB, Fisher PB, Dent P (2001) Hepatitis B virus X protein increases expression of p21(Cip-1/ WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology 34(5): 906–917
284. Gearhart TL, Bouchard MJ (2011) The hepatitis B virus HBx protein modulates cell cycle regulatory proteins in cultured primary human hepatocytes. Virus Res 155(1):363–367
285. Gearhart TL, Bouchard MJ (2010) Replication of the hepatitis B virus requires a calciumdependent HBx-induced G1 phase arrest of hepatocytes. Virology 407(1):14–25
286. Yamashita M, Emerman M (2006) Retroviral infection of non-dividing cells: old and new perspectives. Virology 344(1):88–93
287. Ford HL, Parade AB (1999) Cancer and the cell cycle. J Cell Biochem 32–33(suppl): 166–172
288. Tralhao JG, Roudier J, Morosan S, Giannini C, Tu H, Goulenok C, Carnot F, Zavala F, Joulin V, Kremsdorf D, Brechot C (2002) Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci U S A 99(10):6991–6996
289. Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, Hsu MT, Tsai TF (2006) Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 340(3):916–928
290. Hodgson AJ, Keasler VV, Slagle BL (2008) Premature cell cycle entry induced by hepatitis B virus regulatory HBx protein during compensatory liver regeneration. Cancer Res 68(24):10341–10348
291. Quetier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, Lamant C, Brunelle MN, Soussan P, Kremsdorf D (2013) Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. J Hepatol 59(2): 285–291
292. Mahieux R, Gessain A (2007) Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol Malig Rep 2(4):257–264
293. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P, HCV Collaborative Group (2004) The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 19(4):904–909
294. Matsuoka M, Jeang KT (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7(4):270–280
295. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I (1981) Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 78(10):6476–6480
296. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K (1984) Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 81(8): 2534–2537
297. Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R, Narayanan A, Kashanchi F (2012) HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol 3:406
298. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR, Guedes AC, Carneiro- Proietti AB (2010) Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23(3):577–589
299. Franchini G, Nicot C, Johnson JM (2003) Seizing of T cells by human T-cell leukemia/ lymphoma virus type 1. Adv Cancer Res 89:69–132
300. Marriot SJ, Semmes OJ (2005) Impact of HTLV-1 Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 24(39):5986–5995
301. Lemoine FJ, Marriott SJ (2001) Accelerated G(1) phase progression induced by the human T cell leukemia virus type I (HTLV-I) Tax oncoprotein. J Biol Chem 276(34): 31851–31857
302. Ohtani K, Iwanaga R, Arai M, Huang Y, Matsumura Y, Nakamura M (2000) Cell typespecifi c E2F activation and cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. J Biol Chem 275(15):11154–11163
303. Haller K, Wu Y, Derow E, Schmitt I, Jeang KT, Grassmann R (2002) Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 22(10):3327–3338
304. Kehn K, Fuente Cde L, Strouss K, Berro R, Jiang H, Brady J, Mahieux R, Pumfery A, Bottazzi ME, Kashanchi F (2005) The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 24(4):525–540
305. Iwanaga R, Ohtani K, Hayashi T, Nakamura M (2001) Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene 20(17):2055–2067
306. Suzuki T, Narita T, Uchida-Toita M, Yoshida M (1999) Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Virology 259(2):384–391
307. Low KG, Dorner LF, Fernando DB, Grossman J, Jeang KT, Comb MJ (1997) Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a. J Virol 71(3):1956–1962
308. Mulloy JC, Kislyakova T, Cereseto A, Casareto L, LoMonico A, Fullen J, Lorenzi MV, Cara A, Nicot C, Giam C, Franchini G (1998) Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol 72(11):8852–8860
309. Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN (1998) Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol 72(2):1165–1170
310. Liu M, Yang L, Zhang L, Liu B, Merling R, Xia Z, Giam CZ (2008) Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle. J Virol 82(17):8442–8455
311. Baydoun HH, Pancewicz J, Bai X, Nicot C (2010) HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression. Mol Cancer 9:302
312. Bellon M, Baydoun HH, Yao Y, Nicot C (2010) HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes. Blood 115(12):2441–2448
313. Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G (2004) HTLV-1- encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 10(2):197–201
314. Bai XT, Baydoun HH, Nicot C (2010) HTLV-I p30: a versatile protein modulating virus replication and pathogenesis. Mol Aspects Med 31(5):344–349
315. Taylor JM, Brown M, Nejmeddine M, Kim KJ, Ratner L, Lairmore M, Nicot C (2009) Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. J Virol 83(22):11467–11476
316. Fukumoto R, Dundr M, Nicot C, Adams A, Valeri VW, Samelson LE, Franchini G (2007) Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J Virol 81(17):9088–9099
317. Albrecht B, Lairmore MD (2002) Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev 66(3):396–406, table of contents
318. Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L, Mulloy JC, Jacobson S, Franchini G (2001) Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol 75(13):6086–6094
319. Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G (2009) In vivo genetic mutations defi ne predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. Blood 113(16):3726–3734
320. Silic-Benussi M, Cavallari I, Zorzan T, Rossi E, Hiraragi H, Rosato A, Horie K, Saggioro D, Lairmore MD, Willems L, Chieco-Bianchi L, D’Agostino DM, Ciminale V (2004) Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc Natl Acad Sci U S A 101(17):6629–6634
321. Kim SJ, Ding W, Albrecht B, Green PL, Lairmore MD (2003) A conserved calcineurinbinding motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated T cell activation. J Biol Chem 278(18):15550–15557
322. Darbinyan A, Darbinian N, Safak M, Radhakrishnan S, Giordano A, Khalili K (2002) Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene 21(36):5574–5581
323. Nascimento R, Parkhouse RM (2007) Murine gammaherpesvirus 68 ORF20 induces cellcycle arrest in G2 by inhibiting the Cdc2- cyclin B complex. J Gen Virol 88(Pt 5): 1446–1453
324. Li H, Baskaran R, Krisky DM, Bein K, Grandi P, Cohen JB, Glorioso JC (2008) Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology 375(1):13–23
325. Knight GL, Turnell AS, Roberts S (2006) Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. J Virol 80(15):7416–7426
326. Poggioli GJ, Dermody TS, Tyler KL (2001) Reovirus-induced sigma1s-dependent G(2)/M phase cell cycle arrest is associated with inhibition of p34(cdc2). J Virol 75(16):7429–7434
327. Patton JT (2008) Segmented doublestranded RNA viruses: structural and molecular biology. Caister Academic Press, Bristol, UK
328. Li L, Gu B, Zhou F, Chi J, Wang F, Peng G, Xie F, Qing J, Feng D, Lu S, Yao K (2011) Human herpesvirus 6 suppresses T cell proliferation through induction of cell cycle arrest in infected cells in the G2/M phase. J Virol 85(13):6774–6783
329. Scarano FJ, Laffi n JA, Lehman JM, Friedrich TD (1994) Simian virus 40 prevents activation of M-phase-promoting factor during lytic infection. J Virol 68(4):2355–2361
330. Yeo KS, Mohidin TB, Ng CC (2012) Epstein– Barr virus-encoded latent membrane protein- 1 upregulates 14-3-3sigma and Reprimo to confer G(2)/M phase cell cycle arrest. C R Biol 335(12):713–721
331. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, Taniguchi T (2000) Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 275(30):22627–22630
332. Mhawech P (2005) 14-3-3 proteins—an update. Cell Res 15(4):228–236
333. Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275(30):23106–23112
334. Davy CE, Jackson DJ, Raj K, Peh WL, Southern SA, Das P, Sorathia R, Laskey P, Middleton K, Nakahara T, Wang Q, Masterson PJ, Lambert PF, Cuthill S, Millar JB, Doorbar J (2005) Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/ cyclin B1 complexes. J Virol 79(7): 3998–4011
335. Morita E, Tada K, Chisaka H, Asao H, Sato H, Yaegashi N, Sugamura K (2001) Human parvovirus B19 induces cell cycle arrest at G(2) phase with accumulation of mitotic cyclins. J Virol 75(16):7555–7563
336. Fehr AR, Yu D (2013) Control the host cell cycle: viral regulation of the anaphase- promoting complex. J Virol 87(16):8818–8825
337. Teodoro JG, Heilman DW, Parker AE, Green MR (2004) The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev 18(16): 1952–1957
338. Bellanger S, Blachon S, Mechali F, Bonne- Andrea C, Thierry F (2005) High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability. Cell Cycle 4(11): 1608–1615
339. Tran K, Kamil JP, Coen DM, Spector DH (2010) Inactivation and disassembly of the anaphase-promoting complex during human cytomegalovirus infection is associated with degradation of the APC5 and APC4 subunits and does not require UL97-mediated phosphorylation of Cdh1. J Virol 84(20): 10832–10843
340. Fehr AR, Gualberto NC, Savaryn JP, Terhune SS, Yu D (2012) Proteasome-dependent disruption of the E3 ubiquitin ligase anaphasepromoting complex by HCMV protein pUL21a. PLoS Pathog 8(7):e1002789
341. Everett RD, Earnshaw WC, Findlay J, Lomonte P (1999) Specifi c destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate- early protein Vmw110. EMBO J 18(6):1526–1538
342. Lomonte P, Sullivan KF, Everett RD (2001) Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J Biol Chem 276(8):5829–5835
343. Belyavskyi M, Braunagel SC, Summers MD (1998) The structural protein ODV-EC27 of Autographa californica nucleopolyhedrovirus is a multifunctional viral cyclin. Proc Natl Acad Sci U S A 95(19):11205–11210
344. Ikeda M, Kobayashi M (1999) Cell-cycle perturbation in Sf9 cells infected with Autographa californica nucleopolyhedrovirus. Virology 258(1):176–188
345. Freed EO, Martin MA (2013) Human immunodefi ciency viruses: replication. In: Knipe DM, Howley PM (eds) Fields virology, 6th edn. Lippincot Williams and Wilkins, Philadelphia, PA, pp 1502–1560
346. Gilbert PB, McKeague IW, Eisen G, Mullins C, Gueye NA, Mboup S, Kanki PJ (2003) Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 22(4):573–593
347. Sharp PM, Hahn BH (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1(1):a006841
348. Zhao RY, Li G, Bukrinsky MI (2011) Vprhost interactions during HIV-1 viral life cycle. J Neuroimmune Pharmacol 6(2):216–229
349. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4(1):65–71
350. Kogan M, Rappaport J (2011) HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 8:25
351. Zhao RY, Elder RT (2005) Viral infections and cell cycle G2/M regulation. Cell Res 15(3):143–149
352. Re F, Braaten D, Franke EK, Luban J (1995) Human immunodefi ciency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 69(11):6859–6864
353. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69(11):6705–6711
354. Goh WC, Manel N, Emerman M (2004) The human immunodefi ciency virus Vpr protein binds Cdc25C: implications for G2 arrest. Virology 318(1):337–349
355. Kamata M, Watanabe N, Nagaoka Y, Chen IS (2008) Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J Virol 82(12):5672–5682
356. Yuan H, Kamata M, Xie YM, Chen IS (2004) Increased levels of Wee-1 kinase in G(2) are necessary for Vpr- and gamma irradiationinduced G(2) arrest. J Virol 78(15): 8183–8190
357. Elder RT, Yu M, Chen M, Zhu X, Yanagida M, Zhao Y (2001) HIV-1 Vpr induces cell cycle G2 arrest in fi ssion yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology 287(2):359–370
358. Bartz SR, Rogel ME, Emerman M (1996) Human immunodefi ciency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 70(4):2324–2331
359. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4:57
360. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA (2007) HIV-1 Vprmediated G2 arrest involves the DDB1- CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 3(7):e85
361. Schrofelbauer B, Hakata Y, Landau NR (2007) HIV-1 Vpr function is mediated by interaction with the damage-specifi c DNAbinding protein DDB1. Proc Natl Acad Sci U S A 104(10):4130–4135
362. Tan L, Ehrlich E, Yu XF (2007) DDB1 and Cul4A are required for human immunodefi - ciency virus type 1 Vpr-induced G2 arrest. J Virol 81(19):10822–10830
363. Mansky LM (1996) The mutation rate of human immunodefi ciency virus type 1 is influenced by the vpr gene. Virology 222(2):391–400
364. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V (2003) Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278(28):25879–25886
365. Li G, Park HU, Liang D, Zhao RY (2010) Cell cycle G2/M arrest through an S phasedependent mechanism by HIV-1 viral protein R. Retrovirology 7:59
366. Li G, Elder RT, Qin K, Park HU, Liang D, Zhao RY (2007) Phosphatase type 2A-dependent and -independent pathways for ATR phosphorylation of Chk1. J Biol Chem 282(10):7287–7298
367. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, Blackett J, Choudhary SK, Camerini D, Nghiem P, Planelles V (2004) Human immunodeficiency virus type 1 Vprmediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma- H2AX focus formation. Mol Cell Biol 24(21):9286–9294
368. Zhao Y, Cao J, O’Gorman MR, Yu M, Yogev R (1996) Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fi ssion yeast Schizosaccharomyces pombe. J Virol 70(9): 5821–5826
369. Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ (2003) Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 278(3):1487–1493
370. Roopchand DE, Lee JM, Shahinian S, Paquette D, Bussey H, Branton PE (2001) Toxicity of human adenovirus E4orf4 protein in Saccharomyces cerevisiae results from interactions with the Cdc55 regulatory B subunit of PP2A. Oncogene 20(38):5279–5290
371. Shtrichman R, Sharf R, Barr H, Dobner T, Kleinberger T (1999) Induction of apoptosis by adenovirus E4orf4 protein is specifi c to transformed cells and requires an interaction with protein phosphatase 2A. Proc Natl Acad Sci U S A 96(18):10080–10085
372. Haoudi A, Daniels RC, Wong E, Kupfer G, Semmes OJ (2003) Human T-cell leukemia virus-I tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response. J Biol Chem 278(39): 37736–37744
373. Poon B, Grovit-Ferbas K, Stewart SA, Chen IS (1998) Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 281(5374):266–269
374. Venkatesan A, Sharma R, Dasgupta A (2003) Cell cycle regulation of hepatitis C and encephalomyocarditis virus internal ribosome entry site-mediated translation in human embryonic kidney 293 cells. Virus Res 94(2):85–95
375. Brasey A, Lopez-Lastra M, Ohlmann T, Beerens N, Berkhout B, Darlix JL, Sonenberg N (2003) The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol 77(7):3939–3949
376. Lin GY, Lamb RA (2000) The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J Virol 74(19):9152–9166
377. Alonso-Caplen FV, Matsuoka Y, Wilcox GE, Compans RW (1984) Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin. Virus Res 1(2):153–167
378. Lim KP, Liu DX (2001) The missing link in coronavirus assembly. Retention of the avian coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical interaction between the envelope and membrane proteins. J Biol Chem 276(20):17515–17523
379. Lontok E, Corse E, Machamer CE (2004) Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site. J Virol 78(11): 5913–5922
380. Machamer CE, Mentone SA, Rose JK, Farquhar MG (1990) The E1 glycoprotein of an avian coronavirus is targeted to the cis Golgi complex. Proc Natl Acad Sci U S A 87(18):6944–6948
381. Park HU, Jeong JH, Chung JH, Brady JN (2004) Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNAdamage induced G2 arrest mediated by Chk1. Oncogene 23(29):4966–4974
382. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23(7):1342–1353
383. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein–Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81(12):6718–6730
384. Liu B, Hong S, Tang Z, Yu H, Giam CZ (2005) HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Proc Natl Acad Sci U S A 102(1):63–68
385. Kim S, Park SY, Yong H, Famulski JK, Chae S, Lee JH, Kang CM, Saya H, Chan GK, Cho H (2008) HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 27(24):3457–3464
386. Chabes AL, Pfl eger CM, Kirschner MW, Thelander L (2003) Mouse ribonucleotide reductase R2 protein: a new target for anaphase- promoting complex-Cdh1- mediated proteolysis. Proc Natl Acad Sci U S A 100(7):3925–3929
387. Wiebusch L, Bach M, Uecker R, Hagemeier C (2005) Human cytomegalovirus inactivates the G0/G1-APC/C ubiquitin ligase by Cdh1 dissociation. Cell Cycle 4(10):1435–1439
388. Bornholdt ZA, Noda T, Abelson DM, Halfmann P, Wood MR, Kawaoka Y, Saphire EO (2013) Structural rearrangement of Ebola Virus VP40 begets multiple functions in the virus life cycle. Cell 154(4):763–774
389. Ferreon AC, Ferreon JC, Wright PE, Deniz AA (2013) Modulation of allostery by protein intrinsic disorder. Nature 498(7454):390–394